Certified Nutrition Specialist
About the job
- Maintain an active Certified Nutrition Specialist (CNS) credential in good standing with the Board for Certification of Nutrition Specialists.
- Have at least 1 year of experience providing individualized nutrition counseling or medical nutrition therapy to patients with obesity, diabetes, or other cardiometabolic conditions.
- Be legally permitted to provide medical nutrition therapy in at least one state where Mochi sees patients; a state nutritionist license or certification is required for insurance-covered visits and is strongly preferred.
- Have individual professional liability (malpractice) insurance or be willing to obtain it before the start date.
- Be proficient in online scheduling tools, electronic medical record systems, and video-visit coordination.
- Be skilled in motivational interviewing and patient education.
- Be comfortable working in a dynamic, evolving startup environment.
- Conduct one-on-one virtual medical nutrition therapy and nutrition counseling visits, including personalized meal planning.
- Provide nutrition counseling across multiple specialty areas while recognizing the link between nutrition and whole-body health.
- Build rapport, credibility, and engagement with patients through communication.
- Use motivational interviewing to guide patients toward sustainable lifestyle change.
- Document visits in the electronic medical record using nutrition note templates.
- Stay current with research on obesity medicine, GLP-1 therapy and nutrition, binge eating disorder, and emerging specialty areas.
- Practice only in states where legally permitted to provide medical nutrition therapy and only with patients located in those states.
- Adapt to a fast-paced startup environment and contribute to team-wide improvements.
- Hold a current state license or certification as a nutritionist in one or more of Florida, New York, Washington, North Carolina, Maryland, Pennsylvania, Illinois, Minnesota, Massachusetts, Kentucky, Connecticut, New Mexico, Montana, Delaware, North Dakota, the District of Columbia, or Alaska; CNS candidates practicing in other states are also encouraged to apply.
- Have experience with GLP-1 or other anti-obesity medications and their nutrition considerations.
- Have experience or interest in nutrition as it relates to dermatology, hormone replacement therapy, mental health, longevity, or hair loss.
- Be bilingual in English and Spanish.
About the company
Mochi Health provides telehealth obesity treatment with personalized care using FDA-approved medications. Patients join a subscription that includes medical consultations and prescribed therapies, with options for cost-effective compounded generics. It focuses on underserved groups such as the uninsured, people facing language or cultural barriers, and residents of rural areas to remove access barriers in care. The goal is to make effective obesity treatment accessible and affordable by bundling ongoing care with affordable medication options.
Company Size
N/A
Company Stage
Seed
Total Funding
$550K
Headquarters
San Francisco, California
Founded
2022
Get referred to Mochi Health
See people who can refer or advise you
Simplify's Take
What believers are saying
- Mochi launched insurance-based plans on May 27, 2025, expanding addressable insured demand.
- Mochi still hires aggressively in 2026, signaling growth in engineering, product, and clinical operations.
- Aequita’s shutdown forced pharmacy diversification, reducing future supply concentration risk across partners.
What critics are saying
- Eli Lilly’s April 20, 2026 case survived dismissal, keeping Mochi exposed through 2026.
- Washington regulators shut Aequita in 2025 over sterile-compounding failures, damaging trust in Mochi sourcing.
- Patient billing complaints and separate cancellation workflows create churn risk and recurring BBB disputes.
What makes Mochi Health unique
- Mochi Health combines physician visits, dietitians, and insurance help under one telehealth workflow.
- Mochi Health’s pricing stays flat by dose, simplifying long-term GLP-1 budgeting.
- Mochi Health keeps nationwide pharmacy access after Aequita’s 2025 shutdown, avoiding single-site dependency.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Unlimited Paid Time Off
401(k) Retirement Plan
401(k) Company Match
Wellness Program
Commuter Benefits
Company News
Sapho Bio, a biotechnology company developing a rapid microbiology release platform for precision medicine, announces over $5M in secured funding in an oversubscribed seed round, USP<1223> validation, and availability of rapid sterility test results.
Eli Lilly lawsuit against weight-loss drug seller gets another shave. The pharma giant claims Mochi Health and its pharmaceutical supplier conspired to sell altered, compounded versions of popular weight-loss drugs like Zepbound and Mounjaro in a way that misled consumers and amounted to unfair competition. SAN FRANCISCO (CN) - A federal judge Tuesday further trimmed a lawsuit brought by Eli Lilly and Co. against Mochi Health, a telehealth company that sells compounded versions of tirzepatide drugs Zepbound and Mounjaro, and its pharmaceutical supplier. U.S. District Judge Jacqueline Scott Corley partially granted Mochi Health's motion to dismiss Lilly's second amended complaint, while dismissing claims against Aequita and Mochi Health under the Lanham Act. She advanced claims against Aequita Pharmacy and its parent company, Aequita Corporation, under California's Unfair Competition Law. "Here, Lilly has plausibly alleged the Aequita defendants participated in a conspiracy to violate the UCL through the corporate practice of medicine. However, Lilly has failed to plausibly allege either the Mochi medical defendants or the Aequita defendants were involved in a conspiracy to violate the Lanham Act," the Joe Biden appointee wrote. In its second amended complaint, Lilly claims Mochi Health hires the physicians working at its medical entities, known as Mochi Medical, advertises for them and provides "diagnostic protocols" related to obesity medicine. Moreover, according to Lilly, Mochi Health has unilaterally altered existing compounded medication doses for its customers for business reasons rather than medical ones. The corporate practice of medicine, where business entities without a medical license and motivated by making profits rather than doctors decide on medical care, is prohibited in California. Lily further claimed Aequita's corporate entities - who are controlled by Abraham Chaibi, the husband of Mochi Health CEO Myra Ahmad - had a financial incentive to continue Mochi Health's unlawful practices, accusing Aequita Pharmacy of having "turned a blind eye" to the identical prescriptions it was compounding and complying with Ahmad's directions to cut costs. Compounded versions of popular weight loss drugs don't require approval from the Food and Drug Administration and, according to large drugmakers, are not as rigorously tested as FDA-approved drugs for safety, efficacy and quality. Corley found Lilly provided enough evidence to reasonably infer Aequita knew of the scheme to violate the state's unfair competition law - noting Ahmad had "significant control" over Aequita's procedures and methods for filling prescriptions - and had "significant financial motivation" to participate in the conspiracy. She also found Lilly plausibly claimed Aequita followed the directives of Ahmad to fill prescriptions and implement certain practices to maximize profits, advancing Mochi Health's corporate practice of medicine. "Given the allegations regarding Mochi Health's influence on pharmacy practices, the close relationship between Ms. Ahmad and Mr. Chaibi, and the shared financial benefit across the defendant entities, it is also reasonable to infer the Aequita defendants knew of the conspiracy's aim," Corley wrote. However, she found Lilly failed on its claim that Mochi Health and Aequita conspired to commit false advertising under the Lanham Act, writing that Lilly's assertion that Mochi Health and Mochi Medical colluded to increase revenue of their tirzepatide drug is not enough to claim false advertising. "In short, Lilly has not alleged facts that plausibly support an inference the Mochi Medical defendants' conduct advanced the aim of the conspiracy; namely, to falsely advertise the compounded medication," she wrote. Similarly, Corley found Lilly needed to show how Aequita advanced the claimed false advertising scheme beyond just selling the compounded drug. "False advertising is the proper object of the conspiracy, and Lilly similarly fails to allege facts showing the Aequita Defendants committed any act in furtherance of that aim," she wrote. An Eli Lilly spokesperson touted the ruling's silver lining. "The vourt's decision confirms that Lilly can proceed on all three of its claims - including that Mochi engaged in a civil conspiracy to violate state law restrictions on the corporate practice of medicine," the spokesperson said. "This decision follows numerous other rulings Lilly has obtained in federal courts against the practices of telehealth companies, medspas, and mass compounders, including more than a dozen permanent injunctions. Patients deserve real medicine they can trust, and we will continue to take action against those who put patients at risk." Representatives for the defendants did not respond to a request for comment by press time. Corley granted Mochi Health's motion to dismiss the lawsuit last year, finding Lilly had failed to articulate how it was harmed by the rival seller of weight-loss drugs. Then, in April, she partially granted Mochi Health's second attempt to get the lawsuit thrown out, axing Lilly's claims under the Lanham Act while greenlighting state unfair competition claims. She said in Tuesday's order that Lanham Act claims against the defendants would be dismissed without leave to amend unless the pharma giant discovers facts that support a conspiracy under the statute.
Mochi Health cost: what you actually pay. Mochi Health cost, verified July 2026: the $79 membership plus medication makes the real all-in ~$178/mo semaglutide, ~$278/mo tirzepatide. Full breakdown. Nouri Editorial Team Medically reviewed by Amber Patel, MD · Jul 15, 2026 Medically reviewed by Amber Patel, MD · Last updated July 15, 2026. Nouri content is reviewed by licensed clinicians and updated as guidance changes. Disclosure: This is published by Nouri, a telehealth provider that also offers compounded GLP-1 medication and competes with Mochi Health. nouri has kept the facts sourced and dated, and noted where Mochi is the stronger choice. Mochi figures were verified on joinmochi.com and third-party sites as of July 2026 and may change - confirm current pricing at the source. The short answer: Mochi Health's real cost is two separate charges: a $79/month membership plus the medication. Compounded semaglutide is "starting at $99/month" and tirzepatide "starting at $199/month" - but neither includes the mandatory $79 membership, so the true all-in cost is about $178/month for semaglutide and $278/month for tirzepatide. The medication price is flat across doses, and Mochi can bill insurance for the visit side (not the compounded drug). The most common complaints, per the BBB, are billing and cancellation - largely because the membership and medication are two subscriptions you have to cancel separately. Compounded medications from any provider, including Mochi and Nouri, are not FDA-approved. * Two fees, not one: $79/month membership plus medication ($99 sema / $199 tirz) - the "from $99" headline leaves the membership out. * True all-in: about $178/month (semaglutide) or $278/month (tirzepatide) cash-pay. * Insurance angle: Mochi can bill insurance for the visit/membership side and help with prior authorizations - a real advantage if you're insured. The compounded drug itself stays cash-pay. * Cancellation trap: membership and medication are separate subscriptions; cancelling one doesn't cancel the other - the root of most billing complaints (BBB rating B-). * Genuine strengths: registered-dietitian support, flat price by dose, and a large body of positive Trustpilot reviews. How much does Mochi Health cost? Mochi's pricing splits into two charges that are easy to read as one. There's a membership fee - $79/month standard (a $39 first month for new customers), lower on prepaid terms - and a separate medication fee: compounded semaglutide starting at $99/month and compounded tirzepatide starting at $199/month, with shipping included. Put together, here's the true cash-pay cost, verified on joinmochi.com as of July 2026: | / | Membership | Medication | All-in / month | | Semaglutide | $79/mo | from $99/mo | ~$178/mo | | Tirzepatide | $79/mo | from $199/mo | ~$278/mo | Prices observed on joinmochi.com in July 2026; the $79 membership is added to the medication price to show all-in cost. A $39 first-month membership promo and multi-month prepay can lower the membership portion. Figures may change - verify at the source. Two fair points in Mochi's favor. The medication price is flat across the published dose range - it doesn't climb as you titrate up. And Mochi's membership does buy real things: video visits with a physician and a registered dietitian, ongoing support, and help with insurance prior authorizations. The membership isn't a junk fee; it's just a fee the "from $99" number doesn't show. Does Mochi Health take insurance? Partly, and this is one of Mochi's genuine advantages. Mochi can bill insurance for the visit and membership side (its "Wellness Plus" plan is built around qualifying insurance) and assists with prior authorizations and letters of medical necessity if you're pursuing a branded GLP-1 your plan might cover. What insurance does not cover is the compounded medication itself - that stays cash-pay at Mochi, as it does at every compounded-GLP-1 provider. So if you're insured and want help working your benefits, Mochi offers something a pure cash-pay provider can't. Is Mochi Health legit? Yes - Mochi is a real, licensed telehealth company connecting patients with board-certified physicians and registered dietitians, and it has a large base of positive reviews (a Trustpilot rating around 4.3-4.5 across more than 15,000 reviews as of July 2026). A complete picture also includes the friction: its BBB rating is B- (not accredited), with over 1,300 complaints in three years - most about billing and cancellation. Mochi also does not publicly name its current compounding pharmacy; its former in-house pharmacy in Washington closed in 2025 after a state regulatory action, and Mochi now uses outside partner pharmacies it identifies on the prescription label rather than on its site. And like several telehealth compounders, Mochi is named in ongoing marketing-related litigation from a brand manufacturer - a commercial dispute, not an FDA safety finding. None of this makes Mochi illegitimate; it means the pharmacy transparency and billing terms are worth checking before you enroll. How do you cancel Mochi Health? Carefully - this is the single biggest source of complaints. Because the membership and medication are billed as two separate subscriptions, cancelling one does not cancel the other, and many BBB complaints describe being charged the $79 membership after believing they'd cancelled. Prescription medication sales are generally final and non-refundable, and prepaid membership refunds depend on the plan terms. If you enroll, cancel both subscriptions explicitly and keep records. Mochi Health vs Nouri: an honest comparison. As a competing provider, here's the even-handed version, including where Mochi is the better pick. | / | Nouri | Mochi Health | | Membership fee | None | $79/month (separate) | | Semaglutide, all-in (best tier) | $120/mo (6-month) | ~$178/mo | | Tirzepatide, all-in (best tier) | $175/mo (6-month) | ~$278/mo | | Price at higher doses | Same, any dose | Flat by dose | | Insurance help | Cash-pay only | Bills visit side; PA support | | Compounding pharmacy | Named (Jungle Jim's, VialsRX) | Not publicly named | | Money-back guarantee | 30-day, on 3- & 6-month plans | Medication final-sale | Nouri and Mochi figures as of July 2026; verify current terms with each provider. Where Mochi is the stronger choice: if you're insured and want a provider that bills your benefits for the visit side and helps with prior authorizations, or if you want registered-dietitian-led care and a big review base, Mochi offers things Nouri doesn't. Where Nouri fits better: if you'd rather pay one all-in price with no separate membership, want tirzepatide at a lower all-in cost (~$175 vs ~$278), prefer a provider that names its pharmacy, or want a money-back guarantee. Nouri's model is built around one all-inclusive price with no membership fee; you can also see how the major compounded-GLP-1 providers compare on a published rubric or read its reviews of Ivim Health, Henry Meds, and Noom Med. Frequently asked questions. How much does Mochi Health cost per month? All-in, about $178/month for compounded semaglutide and $278/month for tirzepatide - that's the $79 membership plus the "from $99" (sema) or "from $199" (tirz) medication price. The headline medication price excludes the required membership. Is there a separate membership fee at Mochi? Yes - $79/month (a $39 first month for new customers), separate from and on top of the medication price. It covers video visits with a physician and registered dietitian, ongoing support, and insurance prior-authorization help. Mochi can bill insurance for the visit/membership side and help with prior authorizations, but the compounded medication itself is cash-pay - insurance doesn't cover the compounded drug at Mochi or any provider. Yes - it's a licensed telehealth provider with board-certified physicians and dietitians and a strong Trustpilot rating. Note a B- BBB rating with billing/cancellation complaints, and that Mochi doesn't publicly name its compounding pharmacy. Compounded GLP-1s from any provider are not FDA-approved. How do I cancel Mochi Health? Cancel both the membership and the medication subscriptions separately - cancelling one doesn't stop the other, which is the most common billing complaint. Medication is generally final-sale; keep records of your cancellation. Does Mochi's price change at higher doses? No - the medication price is flat across the published dose range, so titrating up doesn't raise the medication cost. Sources. * Mochi Health - pricing, medications, and FAQ pages (joinmochi.com), verified July 2026. joinmochi.com * Better Business Bureau - Mochi Health profile (B-, complaint categories). bbb.org * Trustpilot - Mochi Health reviews. trustpilot.com * FDA - FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. fda.gov Comparing your options? See if you qualify with Nouri - one all-inclusive price with no separate membership fee, the same at any dose, from a named pharmacy. A five-minute intake, reviewed by a U.S.-licensed physician. This article is educational and reflects publicly available information about Mochi Health as of July 2026, which may change; verify current details with Mochi directly. Nouri is a competing telehealth provider - see the disclosure above. Compounded semaglutide and tirzepatide from any provider, including Mochi and Nouri, are not FDA-approved and are not therapeutically equivalent to Wegovy, Ozempic, Zepbound, or Mounjaro. Nouri connects patients with licensed, independent physicians who make all prescribing decisions. Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before starting or changing any medication or treatment. Licensed providers review patient assessments before making clinical decisions.
Are GLP-1 compounds safe? Not from this SF company and WA supplier, whistleblowers say. San Francisco-based weight loss startup Mochi Health partnered with pharmaceutical supplier, Aequita Pharmacy, to make GLP-1 compounded medication. State inspectors said Aequita's practices put people's safety at serious risk of harm and death. By Candice Nguyen and jeremy carroll - published june 4, 2026 - updated on june 5, 2026 at 11:56 am. GLP-1 medications are the hottest way to lose weight, but are all versions of the drug being marketed to you safe? A San Francisco-based weight loss startup, Mochi Health, is currently under a firestorm of scrutiny after working with pharmaceutical supplier Aqueita Pharmacy, which is in Kirkland, Washington. Partnering with the NBC station in Seattle, Washington, NBC Bay Area's Investigative Unit obtained public records showing whistleblowers went to state inspectors last year with a long list of patient safety complaints against Aequita with which Mochi's CEO Myra Ahmad was directly involved, they said. About 800 miles north of Mochi Health's headquarters at 333 Bush Street in San Francisco's Financial District, Mochi worked with Aequita to create GLP-1 compounded medication - at one point shipping 20,000 prescriptions to patients a week across the U.S., inspectors said in their findings. GLP-1 compounds are mixed by pharmacies to mimic brand name weight loss drugs. They're not FDA approved and the federal agency says they can be risky. Whistleblower reports, state findings As Ahmad took to social media talking about Mochi's growth and cheaper GLP-1 options for patients, Aequita pharmacy staff met with state inspectors in 2025 sharing ring videos from the facility. The videos appear to show Aequita's Head of Operations bring in unlicensed temporary workers to process prescriptions. The workers were picked up at home improvement store parking lots, according to six pharmacy employees who spoke with King 5, the NBC station in Seattle. "They would come over to our main facility...and actually handle the pharmaceuticals themselves," former Aequita lab manager Paul Meyers said. "They didn't have any state licensing." Regulators substantiated this complaint. They also found Aequita allowed untrained pharmacy assistants to compound the GLP-1 prescriptions and even directed the untrained pharmacy workers to compound the drugs without proper supervision. According to the state's report, whistleblowers told investigators Ahmad made a lot of the risky cost-cutting decisions at Aequita. For instance, one employee said Ahmad asked her to find the unlicensed temporary workers to specifically help "handle sterile compounded drugs and assemble kits for shipping and delivery to patients." Expired drugs, glass particles in vials, and Otter Pops Whistleblowers also told investigators, according to the state's report, that Ahmad and Aequita's Head of Operations decided to switch to cheap medicine vials that ended up breaking and shattering. In its determination, the state said witnesses reported seeing glass particles in some of the compounded product. It's unclear if it made it to patients. Also in their findings, inspectors said they discovered expired GLP-1 prescriptions that were going to be mailed out to patients. At least three had been expired for nearly nine months. Then, when the pharmacy ran out of ice packs to ship with the prescriptions because the medication needs to be kept cold during transit, inspectors said staffers alleged Ahmad suggested using frozen Otter Pop popsicles instead. Patients complained online that some of the popsicles leaked, spilling all over their medication, which the state mentioned in its report. Video: Regulators visit GLP-1 supplier unannounced In March 2025, Washington Department of Health inspectors visited one of Aequita's warehouses unannounced. They were responding to whistleblower reports, which included allegations the pharmacy moved GLP-1 drug ingredients across the street to hide them from inspection. Video from that visit obtained through a public records request by NBC Bay Area and the NBC station in Seattle shows a warehouse manager denying knowledge of any attempts to evade inspectors. "As far as I know there's nothing from the, the pharmacy...This is just storage for the packaging and stuff like that," the manager told regulators during the inspection. "Well, that's not necessarily true. I can tell you that...that's not packaging," an inspector responded opening a refrigerator next to the warehouse manager. In the refrigerator were bags of peptide base powders that, according to the state, Aequita used in its GLP-1 compounds. Business records show, months before, Myra Ahmad formed a wholesaler company, USA Distribution LLC, linked to that warehouse. Inspectors said USA Distribution wasn't licensed to be a wholesaler yet when inspectors found the powders. As a result of the inspection and its investigation into the whistleblower reports, the Washington Department of Health issued Aequita a Notice of Immediate Jeopardy. The regulator said the pharmacy's "deficient practices... have placed the health and safety of individuals at risk of serious injury, serious harm, serious impairment or death." Washington state officials said Aequita Pharmacy closed this past April. Mochi Health's CEO avoids questions, no response from Aequita NBC Bay Area's Investigative Unit has tried to speaking with someone at Aequita and Myra Ahmad about these allegations since April, but we haven't received a response. At the Livelong Women's Health Summit in San Francisco last March, NBC Bay Area tried speaking with Ahmad in person. She didn't answer any questions and walked away. In a booming industry that's marketing the hottest way to lose weight, Mochi is still offering GLP-1 compounded medication to patients, according to its website, working with other pharmacies nationwide. Candice Nguyen is the senior investigative reporter on this story. If you have a question or comment, email her at [email protected]. NBC Bay Area's senior investigator Candice Nguyen analyzed the controversy surrounding a Bay Area-based weight loss start-up after reports revealed multiple complaints.
Company secures $5M in funding to accelerate its rapid testing platformUSP Validation achieved,...